AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial
Go back to AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 TrialAbbVie (NYSE: ABBV) | Delayed: 169.54 +1.65 (0.98%) | |||||
---|---|---|---|---|---|---|
Previous Close | $167.89 | 52 Week High | $68.12 | |||
Open | $168.59 | 52 Week Low | $50.71 | |||
Day High | $170.37 | P/E | 36.78 | |||
Day Low | $168.22 | EPS | $4.61 | |||
Volume | 4,084,107 |